Common Contracts
3 similar Underwriting Agreement contracts by Aileron Therapeutics, Inc., BioNano Genomics, Inc, Liqtech International Inc
4,273,505 SHARES OF COMMON STOCK WARRANTS TO PURCHASE 4,273,505 SHARES OF COMMON STOCK AILERON THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 1st, 2024 • Aileron Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Aileron Therapeutics, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Aileron Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Titan Partners Group LLC, a division of American Capital Partners, LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
15,635,850 Shares1 of Common Stock 30,425,000 Pre-Funded Warrants to Purchase Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 17th, 2022 • Liqtech International Inc • Misc industrial & commercial machinery & equipment • New York
LiqTech International, Inc., a Nevada corporation (the “Company”) proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), (i) an aggregate of 15,635,850 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company and (ii) 30,425,000 pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”) at an exercise price of $0.001 per share. The terms of the Pre-Funded Warrants are set forth in the form of Pre-Funded Warrant attached hereto as Exhibit B. The Company has also granted to the Underwriters an option to purchase up to 6,900,000 additional shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this “Agreement”) are herein collectively called the “Shares,” the Firm Shares and the
BIONANO GENOMICS, INC. UNDERWRITING AGREEMENT [ ] UnitsUnderwriting Agreement • August 15th, 2018 • BioNano Genomics, Inc • Laboratory analytical instruments • New York
Bionano Genomics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Roth Capital Partners, LLC is acting as representative (the “Representative”), an aggregate of [ ] units (each a “Unit” and collectively, the “Units”), each consisting of one share of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (the “Firm Shares”) and one warrant (each a “Firm Warrant” and collectively, the “Firm Warrants”) to purchase one share of Common Stock (collectively, the “Firm Units”). The Common Stock that is issuable upon the exercise of either the Firm Warrants or the Option Warrants (as defined below) to be issued in this offering shall be referred to herein as the “Warrant Shares.” The Company also proposes to grant to the Underwriters, upon the terms and conditions set forth in Section 4 hereof,
